The team approach to patient care

Published Date: 08 Mar 2023

Encouraging doctors to work as a team on data development and patient care could be one way to improve the condition of stressed GPs, according to a new study.

Read Full News

Latest News

Dry Eye Drug Does Well in Study, but FDA Remains Unconvinced

The drug, reproxalap, led to reductions in symptoms of dry eye, but regulators have repeatedly refused to approve it for this condition.

Sarcoid Uveitis: 1 in 3 Achieve Remission, Relapses Rare

Remission is achievable and relapses are uncommon in patients with sarcoid uveitis, although those with swelling in the macular region may experience delayed remission.

Female Eye Doctors Earn Less Across All Ranks

Women in academic ophthalmology earn less than men across all ranks, with a pay-gap over a full career of roughly $1 million, a study finds.

US FDA Declines to Approve Aldeyra's Eye Disorder Drug, Shares Slump

The U.S. Food and Drug Administration declined to approve Aldeyra Therapeutics' drug for a type ⁠of eye disease, the company said on Tuesday, sending its shares plunging...

Light Therapy May Improve Vision in Patients With Dry AMD

Light therapy with multiple wavelengths may safely improve vision, reduce new retinal damage, and improve vision related quality of life in patients with dry age related macular degeneration.

Spanish Researchers Develop Low-cost Artificial Cornea From Fish Scales

Researchers at Spain's University of Granada have developed an artificial cornea made from the scales ⁠of several fish species commonly found in markets, which could become...

Todays Updates

Which Risk Model Better Identifies High-Risk Smoldering MM?

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering multiple myeloma by the AQUILA trial inclusion criteria vs 2/20/20 risk model.

Todays Updates

Which Risk Model Better Identifies High-Risk Smoldering MM?

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering multiple myeloma by the AQUILA trial inclusion criteria vs 2/20/20 risk model.

Latest News

The drug, reproxalap, led to reductions in symptoms of dry eye, but regulators have repeatedly refused to approve it for this condition.

Remission is achievable and relapses are uncommon in patients with sarcoid uveitis, although those with swelling in the macular region may experience delayed remission.

Women in academic ophthalmology earn less than men across all ranks, with a pay-gap over a full career of roughly $1 million, a study finds.

The U.S. Food and Drug Administration declined to approve Aldeyra Therapeutics' drug for a type ⁠of eye disease, the company said on Tuesday, sending its shares plunging...

Light therapy with multiple wavelengths may safely improve vision, reduce new retinal damage, and improve vision related quality of life in patients with dry age related macular degeneration.

Researchers at Spain's University of Granada have developed an artificial cornea made from the scales ⁠of several fish species commonly found in markets, which could become...

News All Time

Metabolic Syndrome Tied to Glaucoma Risk

Metabolic syndrome, rather than BMI or waist circumference, is linked to an increased likelihood of glaucoma and may better identify adults who could benefit from closer eye screening.

Two Biologics Show Comparable Benefit in Uveitis

Adalimumab and tocilizumab perform similarly in controlling inflammation while reducing the use of corticosteroids at week 16 in patients with refractory, noninfectious uveitis.

Ocular Therapeutix Plunges as Modest Benefit Overshadow Trial Win Over Regeneron's Eylea

Ocular Therapeutix's experimental eye drug showed superiority to Regeneron's Eylea in a key late-stage trial, but ⁠its modest advantage and higher rates of certain side...

Early Retinal Fluid Drying May Extend Injection Gaps in AMD

Rapid drying of retinal fluid with faricimab injections may help identify patients with neovascular age-related macular degeneration who can safely extend time between injections.

PDS Ranibizumab Retains Visual Acuity Gains in nAMD, with John Kitchens, MD John W. Kitchens, MD

The ongoing Archway-Portal extension study indicates the lasting efficacy and safety of ranibizumab dosing via the Port Delivery System.

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

The HCPFive: Top News for Healthcare Providers from the Week of 12/28

FDA Issues Complete Response Letter for ONS-5010 for Wet AMD

Ophthalmology in 2025: Year in Review

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

6 Ophthalmology Headlines You Missed in October 2025

New Parameters for Faster Geographic Atrophy Progression Established, with Srinivas Sadda, MD Srinivas Sadda, MD

The pooled sham cohorts of the OAKS and DERBY trials have revealed a series of indicators for faster geographic atrophy lesion growth.

OCU-410 Gene Therapy Preserves Visual Acuity and Slows GA Lesion Progression, with Jay Chhablani, MD Jay Chhablani, MD

Recent phase 1/2 trial data indicate the safety and efficacy of the surgical, subretinal injection in monitoring cellular homeostasis.

Intravitreal UBX1325 Shows Efficacy in Diabetic Retinopathy, DME, with Dante Pieramici, MD Dante J. Pieramici, MD

Results from the BEHOLD and ASPIRE trials indicate the long lasting effects of UBX1325 in improving retinal function and structure.

A three-quarters reduction in the risk of prostate cancer is associated with an annual increase in cardiorespiratory fitness of more than three percent.

Treating advanced prostate cancer

Metastatic breast cancer can be effectively treated with cyclical estrogen and anti-estrogen therapy.

Participate and win cash vouchers

Get updates on the latest events happening around the world

2.

Never in a million years did I think I'd have to limit my chemotherapy.

3.

Novel topical fluorescent imaging technique rapidly and safely detects basal cell carcinoma

4.

Virtual Reality Travel Reduces Cancer Pain.

5.

The Truth About Apple AirPods

1.

All You Need To Know About Cancer Antigen 27-29: Causes, Symptoms & Treatment

2.

A Comprehensive Guide To Understanding Plasma Osmolality

3.

The Rise of Immunotherapy: New Advances in Cancer Treatment

4.

Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer

5.

Unveiling the Secrets of Early Cancer: Emerging Strategies to Decipher Its Biology

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII

2.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

3.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

5.

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

The team approach to patient care

Latest News

Dry Eye Drug Does Well in Study, but FDA Remains Unconvinced

Sarcoid Uveitis: 1 in 3 Achieve Remission, Relapses Rare

Female Eye Doctors Earn Less Across All Ranks

US FDA Declines to Approve Aldeyra's Eye Disorder Drug, Shares Slump

Light Therapy May Improve Vision in Patients With Dry AMD

Spanish Researchers Develop Low-cost Artificial Cornea From Fish Scales

Todays Updates

Which Risk Model Better Identifies High-Risk Smoldering MM?

Todays Updates

Which Risk Model Better Identifies High-Risk Smoldering MM?

Latest News

News All Time

Metabolic Syndrome Tied to Glaucoma Risk

Two Biologics Show Comparable Benefit in Uveitis

Ocular Therapeutix Plunges as Modest Benefit Overshadow Trial Win Over Regeneron's Eylea

Early Retinal Fluid Drying May Extend Injection Gaps in AMD

PDS Ranibizumab Retains Visual Acuity Gains in nAMD, with John Kitchens, MD John W. Kitchens, MD

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

The HCPFive: Top News for Healthcare Providers from the Week of 12/28

FDA Issues Complete Response Letter for ONS-5010 for Wet AMD

Ophthalmology in 2025: Year in Review

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

6 Ophthalmology Headlines You Missed in October 2025

New Parameters for Faster Geographic Atrophy Progression Established, with Srinivas Sadda, MD Srinivas Sadda, MD

OCU-410 Gene Therapy Preserves Visual Acuity and Slows GA Lesion Progression, with Jay Chhablani, MD Jay Chhablani, MD

Intravitreal UBX1325 Shows Efficacy in Diabetic Retinopathy, DME, with Dante Pieramici, MD Dante J. Pieramici, MD

Recommended News For You

Detecting pancreatic cancer through changes in body composition and metabolism

Formaldehyde releasers found in common personal care products used especially by Black and Latina women

FDA OKs Upfront Nivolumab+Chemo for Classic Hodgkin Lymphoma

The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

A three-quarters reduction in the risk of prostate cancer is associated with an annual increase in cardiorespiratory fitness of more than three percent.

Treating advanced prostate cancer

Metastatic breast cancer can be effectively treated with cyclical estrogen and anti-estrogen therapy.

Recommended Articles For You

Unlocking the Potential of CPK Levels: How to Maximize Your Health Benefits

New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma

Potential of Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer

Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.